Načítá se...
Combining immunotherapies for the treatment of prostate cancer
Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great promise for improving outcomes for prostate can...
Uloženo v:
| Vydáno v: | Urol Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6599516/ https://ncbi.nlm.nih.gov/pubmed/29146441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2017.09.024 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|